Sonablate

Executive Summary

Sonablate Corp. is a US-based medical device company focused on minimally invasive focal therapy for prostate diseases, primarily through its Sonablate HIFU system. This high-intensity focused ultrasound platform uses robotic precision and real-time monitoring to ablate diseased prostate tissue, offering a targeted alternative to radical procedures. The company has established a strong global footprint, with regulatory approvals in over 50 countries and FDA clearance in the United States, positioning it as a leader in prostate focal therapy. Sonablate’s technology addresses a growing demand for treatments that reduce side effects while maintaining oncological efficacy, appealing to both patients and healthcare providers seeking less invasive options. Looking ahead, Sonablate is well-positioned to expand its clinical evidence base and commercial reach. Ongoing research is expected to yield long-term outcomes data supporting the durability of HIFU treatment, which could drive adoption among urologists. Additionally, the company may pursue broader indications beyond prostate cancer, such as renal or hepatic tumors, to capture larger market opportunities. Strategic partnerships in underpenetrated regions like Asia and Latin America could further accelerate revenue growth. While competition from other focal therapy modalities exists, Sonablate’s first-mover advantage and established regulatory approvals provide a foundation for sustained leadership.

Upcoming Catalysts (preview)

• Q3 2026Publication of 5-year outcomes from large-scale HIFU registry85% success
• Q4 2026FDA clearance for expanded indication (e.g., renal tumors)40% success
• H1 2026Strategic distribution partnership in China or India60% success